This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/chemspider/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB08807/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08807
rdf:type
n3:Drug
n3:description
Bopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960.
n3:group
approved
n3:indication
For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
owl:sameAs
n6:DB08807 n15:DB08807
dcterms:title
Bopindolol
adms:identifier
n10:D07537 n11:40146 n12:DB08807 n14:355377 n16:PA165958425 n17:Bopindolol
n3:mechanismOfAction
Bopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
n3:synonym
Sandonorm
n3:IUPAC-Name
n4:271B55F4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B55FA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B55F9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B55F6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B55F7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B55F8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B560A-363D-11E5-9242-09173F13E4C5 n4:271B55F2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B55F3-363D-11E5-9242-09173F13E4C5 n4:271B55F0-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B55F1-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:C07AA17
n3:H-Bond-Acceptor-Count
n4:271B5600-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5601-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B55FB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B55FC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B55FE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B55FD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B55FF-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
69010-88-4
n3:Bioavailability
n4:271B5606-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5608-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5609-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B560B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5605-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5604-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5607-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B55F5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5602-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5603-363D-11E5-9242-09173F13E4C5